American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment

David C. Shonka(University of Virginia), Alan L. Ho(Memorial Sloan Kettering Cancer Center), Ashish V. Chintakuntlawar(Mayo Clinic), J.L. Geiger(Cleveland Clinic), Jong Chul Park(Massachusetts General Hospital), Nagashree Seetharamu(Hofstra University), Sina Jasim(Washington University in St. Louis), Amr H. Abdelhamid Ahmed(Massachusetts Eye and Ear Infirmary), Keith C. Bible(Mayo Clinic), Marcia S. Brose(University of Pennsylvania), Maria E. Cabanillas(The University of Texas MD Anderson Cancer Center), Kirsten F. A. A. Dabekaussen(Brigham and Women's Hospital), Louise Davies(Dartmouth College), Dora Dias‐Santagata(Harvard University), James A. Fagin(Memorial Sloan Kettering Cancer Center), William C. Faquin(Harvard University), Ronald Ghossein(Memorial Sloan Kettering Cancer Center), Raj K. Gopal(Massachusetts General Hospital), Akira Miyauchi(Kuma Hospital), Yuri E. Nikiforov(University of Pittsburgh), Matthew D. Ringel(The Ohio State University Wexner Medical Center), Bruce Robinson(The University of Sydney), Mabel Ryder(Mayo Clinic), Eric J. Sherman(Memorial Sloan Kettering Cancer Center), Peter M. Sadow(Harvard University), Jennifer J. Shin(Harvard University), Brendan C. Stack(Southern Illinois University School of Medicine), R. Michael Tuttle(Memorial Sloan Kettering Cancer Center), Lori J. Wirth(Massachusetts General Hospital), Mark Zafereo(The University of Texas MD Anderson Cancer Center), Gregory W. Randolph(Massachusetts Eye and Ear Infirmary)
Head & Neck
March 11, 2022
10.1002/hed.27025
Cited by 110Open Access
Full Text

Abstract

BACKGROUND: The development of systemic treatment options leveraging the molecular landscape of advanced thyroid cancer is a burgeoning field. This is a multidisciplinary evidence-based statement on the definition of advanced thyroid cancer and its targeted systemic treatment. METHODS: An expert panel was assembled, a literature review was conducted, and best practice statements were developed. The modified Delphi method was applied to assess the degree of consensus for the statements developed by the author panel. RESULTS: A review of the current understanding of thyroid oncogenesis at a molecular level is presented and characteristics of advanced thyroid cancer are defined. Twenty statements in topics including the multidisciplinary management, molecular evaluation, and targeted systemic treatment of advanced thyroid cancer are provided. CONCLUSIONS: With the growth in targeted treatment options for thyroid cancer, a consensus definition of advanced disease and statements regarding the utility of molecular testing and available targeted systemic therapy is warranted.

Related Papers

Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Nishant Agrawal, Rehan Akbani, Bülent Arman Aksoy et al.|Cell|2014|3.1k
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
Samuel A. Wells, L. Sylvia, Henning Dralle et al.|Thyroid|2015|2.4k
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Martin Schlumberger, Makoto Tahara, Lori J. Wirth et al.|New England Journal of Medicine|2015|2k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
David M. Hyman, Igor Puzanov, Vivek Subbiah et al.|New England Journal of Medicine|2015|1.7k
<i>PAX8-PPAR</i> γ <i>1</i> Fusion in Oncogene Human Thyroid Carcinoma
Todd G. Kroll, Pasha Sarraf, Lorenza Pecciarini et al.|Science|2000|784